[{"id":"5b8b9528-6301-44fb-9a3a-f2ff7c86719c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04162327","created_at":"2021-01-18T20:17:57.693Z","updated_at":"2024-07-02T16:35:31.890Z","phase":"Phase 1a/1b","brief_title":"A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor","source_id_and_acronym":"NCT04162327","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fidasimtamab (IBI315)"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 11/26/2019","start_date":" 11/26/2019","primary_txt":" Primary completion: 01/27/2022","primary_completion_date":" 01/27/2022","study_txt":" Completion: 06/20/2023","study_completion_date":" 06/20/2023","last_update_posted":"2023-10-24"}]